Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: The three western U.S. cities top the list of the 100 best towns for men in a new ranking compiled by Men's Health magazine, while Charleston, West Virginia, Philadelphia and Birmingham, Alabama are considered the worst. "Anytime we do a best and worst city ranking and a city comes in at the very top like this, it immediately says to us they were consistently strong across the board in pretty much all of the 38 criteria that we looked at," Men's Health Executive Editor Matt Marion said. Boise, which jumped from fifth place last year, scored high marks for the physical and mental health of its residents, its low crime rate and short commuting times - an average of just 18 minutes. "Boise finishing number one was interesting to us because it is a city that would have finished in the top 20, but to come in right at the top is impressive," Marion said. San Francisco, which consistently ranks high in the annual list, impressed with its small percentage of obese people, low number of smokers and highly educated and generally fit population. San Jose had very low death rates from cancer and heart disease, the lowest percentage of smokers in any of the 100 cities in the ranking, and not much crime. Plano, in Texas and Seattle rounded out the top five, followed by Burlington, Vermont, which dropped from the top spot last year. At the opposite end of the list, high cancer rates, violent crime and poor fitness levels assured Birmingham last place. In addition to Philadelphia and Charleston, West Virginia, the bottom five included Toledo, Ohio and St. Louis, Missouri. New York ranked 33rd and Los Angeles was in the middle of the ranking. The magazine compiled the list, now in its 12th year, by ranking the cities on criteria ranging from the cost of living, number of jobless, obesity, crime and death rates, to air quality and the ratio of men to women. It used data from various sources including the U.S. Centers for Disease Control in Atlanta, the National Center for Health Statistics, state cancer registries and federal crime statistics. "The things that we do focus on ultimately are the ones that will make a difference in terms of whether or not you will be happy and healthy," Marion said. The full list can be found here Claim: Idaho, California cities deemed best in U.S. for men.

Answer: U.S. men looking for the best place to find happiness, health and a good quality of life might consider heading to Boise, Idaho, or San Jose and San Francisco in northern California.

Question: Paragraph: Given that this is an illegal substance banned by the U.S. Drug Enforcement Agency, cost as a therapeutic would be difficult to ascertain. We liked that the story took pains to explain that approval of this drug faces many hurdles. This is a tough one. While the story tells us what percentage of patients benefited from treatment, it does not, in fact, quantify the extent of those benefitswhich is precisely what this category is designed to assess. However, the story does do a goodand thoroughjob of describing the benefits in qualitative terms. That said, if the story had only chosen one or two examples of changes in the standardized measures of depression or anxiety, this would have received an enthusiastic "Satisfactory" rating. One strong word of caution though: The story cites one source as saying that psilocybin may one day be used to treat a wide range of mental health issues ranging from drug addiction to obsessive-compulsive disorder. The story offers no evidence to support these claims, which were made by a source associated with an organization that exists specifically to promote research on hallucinogens. Substantial claims require substantial evidence. The story would have been much stronger if it had eliminated the unsubstantiated remarks from the source particularly since they had no bearing on the subject of the story. The story addresses this issue thoroughly. Well done. The story does a good job of both describing the design of the studies and explaining why the study design is relevant. For example, the story notes: "But both [studies] were considered to be double-blind placebo trials the gold-standard of medical research in which subjects are left to guess whether they have gotten the active study drug or an inactive lookalike." This is the sort of thing we like to see. However, we did want to note that in the NYU study, researchers did state in the limitations section that there was "limited blinding" how did that possibly affect the outcomes? No disease mongering here. However, the story should have been more cautious about claims of benefit for conditions ranging far beyond the scope of the research at hand, which focused on mental health problems among people with advanced cancer. The story clearly states who funded the studies, and what that organization's long-term goals are. Further, the story clearly identified individuals quoted in the story who have ties to the studies or the funding organization. Lastly, the story incorporates input from an independent expert. However, the story would have been stronger if there had been a skeptical take on the research, which sawin some other coverage, such as this New York Times piece. The story does not address other treatment options for anxiety or depression, such as talk therapy or other pharmaceutical interventions. The story does a good job here. For example, the story notes: "[F]inding drugs like psilocybin effective is by no means the final hurdle to their widespread availability. None are currently in production, and no for-profit pharmaceutical company would likely invest millions of dollars to bring to market a pill intended effectively for one-time use." Well done. This is a close call. The story does do a good job of placing the work in context in regard to overall research involving hallucinogens. That's enough to earn it a "Satisfactory" rating. However, the story doesn't mention any of the work done in the past 10 years on the use of psilocybin specifically to address anxiety in cancer patients, such as this 2007 study, this one from 2011, or this one from 2013. Are the results from the two new studies consistent with these earlier findings? Do they differ in a meaningful way? That would be good to know. The story does not appear to rely on a news release. Claim: Ingredient in magic mushrooms is shown to ease anxiety and depression in cancer patients in one dose

Answer: The story focuses on two recent studies that find a single application of the hallucinogen psilocybin is effective at providing meaningful relief to cancer patients suffering from severe depression or anxiety. The studies were published in the Journal of Psychopharmacology, and can be found here and here. In some ways, the story is thorough, addressing potential side effects and conflicts of interest very well. The story discusses the potential benefits in depth, which is good, but fails to quantify those benefits which is problematic. The story also does a good job of placing the work in context, highlighting the increasing profile of research into the use of hallucinogens as therapeutic tools for mental health problems. However, the story would have been even stronger if it had discussed the existing literature on the use of psilocybin to address anxiety in cancer patients. We also reviewed twonews releases related to the research: Depression and other mental health struggles are common and significant among people with cancer, especially terminal cancer. This makes it especially important for reporters to write responsibly about studies like those discussed in this story. You want to give readers enough information to help them make informed decisions. You don't want to raise false hopes, or sensationalize the work. Overall, this story does a nice job of handling a delicate subject well.

Question: Paragraph: No costs of treatmentany treatmentare described. The study measured how many men with low-risk prostate cancer (who would be appropriate candidates for watchful waiting) had either surgery or radiation. While the aim of the study was to quantify and report an estimated figure for "overtreatment," the story doesn't really describe that. Viewers could think that all men reported in the story as having low-risk prostate cancer and who were treated with surgery or radiation were overtreated (half of 25,000 men), when the actual study reports 10% of men were overtreated. Major harms of surgery or radiation are providedincontinence and sexual problems. On the flip side, the article also points out that some cancers can be life-threatening (a risk of watchful waiting, although not explicitly stated here is that a man could miss a chance to "cure" his cancer). The story explains that researchers collected records of men who had prostate cancer, so an astute viewer could potentially figure out that this was a cohort study (retrospective). It could be clearer. The story describes the natural history of prostate cancer, and specifically, the fact that it is usually slow-growing and that many men may never need treatment, which is true. However, the anecdotal story, which presumably is a shining example of a watchful waiting perspective, is troublesome. This man reports being bothered by the thought of side effects and yet reports having hormone therapy, which itself has many side effects (including loss of sex drive) and it isn't clear from the story whether this was even indicated for his cancer (so, he could be substituting one harmful treatment for another). The story quotes an expert not related to the research to confirm that prostate cancer is often unnecessary to treat. The story describes four treatment optionssurgery, radiation, hormone therapy, and watchful waiting. However, in the example given, a man who chose not to have surgery or radiation opted for hormone therapy, which can also have significant side effects that weren't discussed. This isn't a good example of a "watchful waiting" strategy. The story mentions 4 treatment options: surgery, radiation, hormonal therapy and watchful waiting. It states that many men choose either surgery or radiation, implying these treatments are widely available and it also relates an anecdotal story of one man choosing some form of watchful waiting, implying this approach is also available (although the man's story, and specifically, the addition of hormone treatment to watchful waiting isn't the traditional view of this approach). The option of watchful waiting, while historically less commonly pursued than other more active treatments, is not new, which the article implies. There's no evidence the story relied solely on a news release. Claim: Prostate cancer being overtreated, study shows

Answer:
The story describes a study which quantifies the number of men who might be overtreated with surgery or radiation for prostate cancer. The story does a nice job of describing the natural history of prostate cancer, that is, that many prostate cancers are slow-growing and that many men don't need treatment, which can have troublesome side effects. The article could have been more clear about the study design and exactly how many men were estimated to have been "overtreated." Viewers are provided information about how many men were candidates for watchful waiting and could easily assume that any man who did not choose this approach was overtreated. Yet the actual study reports 10% of men were "overtreated." The story also strangely reports an anecdotal story of one man who presumably chose watchful waiting. Yet this man also took a course of hormone therapy, which has multiple bothersome side effects related to depletion of nearly all a man's testosterone (side effects like loss of sex drive). It's confusing why this example was chosen, when this isn't normally considered an option for men with low-risk prostate cancer.